Investigational New Drugs

, Volume 17, Issue 2, pp 183–186

Phase II Trial of Suramin in Patients with Metastatic Renal Cell Carcinoma

  • Robert Dreicer
  • David C. Smith
  • Richard D. Williams
  • William A. See
Article

DOI: 10.1023/A:1006331518952

Cite this article as:
Dreicer, R., Smith, D.C., Williams, R.D. et al. Invest New Drugs (1999) 17: 183. doi:10.1023/A:1006331518952

Abstract

This study was conducted to assess the efficacy and toxicity of suramin administered using a fixed dose schedule in patients with advanced renal cell carcinoma. Fourteen eligible patients with advanced renal cell carcinoma were enrolled and treated on a fixed dose schedule of suramin administered over 12 weeks. Suramin was administered by intravenous infusions over 1 hour. None of the 13 evaluable patients demonstrated an objective response. Only 3 patients completed the 12-week therapy course, with the majority developing progressive disease on therapy. The fixed dosage schedule was well tolerated with minimal to moderate toxicity. Suramin in this fixed dose schedule is well tolerated but has no activity in advanced renal cell carcinoma.

carcinomarenal cellneoplasm metastasissuramin

Copyright information

© Kluwer Academic Publishers 1999

Authors and Affiliations

  • Robert Dreicer
    • 1
    • 2
    • 3
  • David C. Smith
    • 4
  • Richard D. Williams
    • 2
    • 3
  • William A. See
    • 2
    • 3
  1. 1.Department of Internal MedicineThe University of IowaIowa CityUSA
  2. 2.he University of Iowa Cancer CenterIowa CityUSA
  3. 3.Department of UrologyThe University of IowaIowa CityUSA
  4. 4.Department of MedicineThe University of MichiganAnn ArborUSA